Observational studyJournal of general internal medicine2014
Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Observational study in Journal of general internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Tough versus soft regulations to promote generic medications in Italy.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy.Cardiology and therapy · 2021Review
- Regularity and Continuity of GP Contacts and Use of Statins Amongst People at Risk of Cardiovascular Events.Journal of general internal medicine · 2021 · on this mapObservational
- Statin Adherence: Does Gender Matter?Current atherosclerosis reports · 2016Review
- When compliance is an issue-how to enhance statin adherence and address adverse effects.Current atherosclerosis reports · 2015Review
- Capsule commentary on Romanelli et al., predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.Journal of general internal medicine · 2014Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify patient demographics and characteristics associated with compliance to statin therapy after switching from branded to generic agents
designRetrospective cohort study using electronic health records and pharmacy claims data from Sutter Health's ambulatory-care medical network PATIENTS: Managed-care beneficiaries, ≥ 18 years of age, who were switched from branded to generic statins between 1 January 2003 and 31 December 2012 MAIN MEASURES: Compliance was calculated as days of therapy dispensed divided by days from first to last generic prescription fill over 6 months, and was defined as a medication possession ratio ≥ 0.80. We used multivariable logistic regression to assess factors associated with compliance. Adjusted ORs and 95% CI were generated. KEY
resultsWe identified 5,156 patients who were switched from branded to generic statins; 73% of patients were compliant in the 6 months after switching. After statistical adjustment, higher compliance was associated with each 10-year increase in age (OR: 1.13; 95% CI: 1.07, 1.19; p < 0.001), receipt of a generic statin equivalent in potency to the prior branded statin (OR: 1.41; 95% CI: 1.16, 1.70; p < 0.001), and compliance with prior branded statin (OR: 4.68; 95% CI: 4.07, 5.39; p < 0.001). Lower compliance was seen among Hispanic patients compared to non-Hispanic white patients (OR: 0.68; 95% CI: 0.52, 0.91; p = 0.009). Also, a switch to a higher potency generic statin, regardless of prior dose/potency, was negatively associated with compliance after switching (OR: 0.87; 95% CI: 0.80, 0.94; p = 0.001).
conclusionsThe majority of patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching. The potential for non-compliance to generic statin therapy, particularly among younger or Hispanic patients or when dose/potency changes are made, should be considered prior to switching. For these patients, counseling or close monitoring may be required to optimize generic interchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.